Echosens

Echosens is wishing everyone a very happy festive season!

🌟 As part of the Echosens Liver Health Super Shaper Award, honorees have the opportunity to donate $10,000 to a charity of their choice, courtesy of Echosens. We’re proud to share that Dr. Jörn M. Schattenberg has chosen to support the Lucie Bolte Stiftung (Lucie Bolte Foundation), based in Germany. Established in 1980 by Erich Bolte in memory of his wife, Lucie, who passed away from liver disease, the foundation honors her wish to help people affected by the disease. 👏 Join us in celebrating the Lucie Bolte Stiftung for its decades-long mission to support those with liver disease and Dr. Schattenberg for choosing to give back through this meaningful foundation. Learn more about the Lucie Bolte Stiftung here: https://lnkd.in/g4AniwmQ #LiverHealthMatters

🎉 Exciting progress in tackling #MASH! The GRIPonMASH consortium, with Echosens as the industry lead, reports strong first-year results in its mission to revolutionize the detection and care of Metabolic dysfunction-Associated SteatoHepatitis (MASH). 📌 Key milestones: 🔹 First patient screened and biobank initiated 🔹Pilot diagnostic GripOnMASH platform developed, powered by Echosens’ Liver Health Management platform 🔹Lifestyle insights gathered for personalized care 🔹Awareness campaigns launched to empower primary care providers Together, we’re paving the way to improved liver health for all. 🚀 #LiverHealthMatters #MASLD

👏 "The capabilities of the LHM platform allow healthcare providers to easily integrate liver care into their workflows, facilitating effective data management and comprehensive liver health assessments..." ➡️ Read the full article here: https://lnkd.in/ez4RqEt7 #LiverHealthMatters #FibroScan

Earning a spot among the top 20 small employers is an incredible honor, but it’s our people who truly make Echosens exceptional. Celebrating together reminds us of the vibrant, collaborative culture that drives our mission to improve liver health and patient lives every day. Thank you to everyone who makes Echosens an extraordinary place to work. Here's to many more achievements ahead! Boston Globe Media #LiverHealthMatters #TopPlacestoWork #Echosens

Echosens is proud to be named one of The Boston Globe’s 2024 Top Places to Work, earning a spot among the top 20 small employers! 🏆 As the leader in liver health, we know that innovation starts with an exceptional team. A heartfelt thank-you to all of our amazing employees—this recognition reflects your passion and dedication to advancing liver health and improving patient lives. 👉 https://lnkd.in/emMaaXH4 Boston Globe Media #LiverHealthMatters #TopPlacestoWork #Echosens

⏰ It is happening tomorrow! Don't miss our #webinar on the Collaborative Approaches of Hepatology and Diabetology Specialists in the Identification and Management of #MASLD patients in Asia-Pacific.   Tailored to everyday clinical practice, this session would provide useful information on: 🔸Interdisciplinary patient care pathways, 🔸Clinical guidelines, 🔸Diagnostic thresholds, 🔸Clinical cases in the management of MASLD in patients with Type 2 Diabetes.   ➡️ Join us today: https://lnkd.in/ebci8bhU Wai-Kay Seto, Paul Lee #LiverHealthMatters

Last week, Echosens held its end-of-year party on the 56th floor of the famous Tour Montparnasse, with a stunning 360° view over Paris. Many employees from the European offices (UK, Germany, Italy, Belgium and Sweden) came and joined the French team to enjoy this exciting evening together. #LiverHealthMatters

📢 “With the increasing prevalence of #MASLD and #MASH, the LHM platform provides essential support for clinicians seeking to catch the disease early, while it’s still reversible,” our Group CEO, Dominique Legros said. 👉 Read the full article now: https://lnkd.in/euGWe5vh #LiverHealthMatters #FibroScan

A new study from Spain reports the utility of #FibroScan® as a screening tool in patients with Alcohol Use Disorders (AUDs), which showed that: 🔸Participation in a screening program for liver fibrosis allows early identification of alcohol-associated liver disease 🔸Participation in a screening program (FibroScan® test & lifestyle counselling) is also associated with improved rates of alcohol abstinence after 6 months of follow up. ➡️ This study emphasizes the therapeutic effects of fibrosis screening in patients with AUD and supports the implementation of these programs in addiction units. Learn more here 👉 https://lnkd.in/egX-BdAM #LiverHealthMatters